BR9813835A - Compound, pharmaceutical composition and method of treatment or prevention of a thromboembolic disorder - Google Patents
Compound, pharmaceutical composition and method of treatment or prevention of a thromboembolic disorderInfo
- Publication number
- BR9813835A BR9813835A BR9813835-9A BR9813835A BR9813835A BR 9813835 A BR9813835 A BR 9813835A BR 9813835 A BR9813835 A BR 9813835A BR 9813835 A BR9813835 A BR 9813835A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- thromboembolic disorder
- prevention
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<B>"COMPOSTO, COMPOSIçãO FARMACêUTICA E MéTODO DE TRATAMENTO OU PREVENçãO DE UMA DESORDEM TROMBOEMBóLICA"<D> A presente invenção descreve heteroaromáticos contendo nitrogênio com PI's orto-substituídos e seus derivados de Fórmula (I) ou suas formas de pró-drogas ou sais farmaceuticamente aceitáveis, em que J é N ou NH e D é orto-substituído para G sobre E e pode ser CH~ 2~NH~ 2~, que são úteis como inibidores de fator Xa.<B> "COMPOUND, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING OR PREVENTING A THROMBOEMBOLIC DISORDER" <D> The present invention describes nitrogen-containing heteroaromatics with ortho-substituted PI's and their derivatives of Formula (I) or their forms of pro-drugs or pharmaceutically acceptable salts, where J is N or NH and D is ortho-substituted for G over E and can be CH ~ 2 ~ NH ~ 2 ~, which are useful as factor Xa inhibitors.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99644797A | 1997-12-22 | 1997-12-22 | |
US10107598P | 1998-09-18 | 1998-09-18 | |
PCT/US1998/026427 WO1999032454A1 (en) | 1997-12-22 | 1998-12-11 | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9813835A true BR9813835A (en) | 2000-10-10 |
Family
ID=26797877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9813835-9A BR9813835A (en) | 1997-12-22 | 1998-12-11 | Compound, pharmaceutical composition and method of treatment or prevention of a thromboembolic disorder |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1042299A1 (en) |
JP (1) | JP2001526268A (en) |
AU (1) | AU1724499A (en) |
BR (1) | BR9813835A (en) |
CA (1) | CA2314401A1 (en) |
IL (1) | IL136637A0 (en) |
WO (1) | WO1999032454A1 (en) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL147317A0 (en) | 1999-07-16 | 2002-08-14 | Bristol Myers Squibb Pharma Co | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR Xa INHIBITORS |
US6329527B1 (en) * | 1999-10-21 | 2001-12-11 | Bristol-Myers Squibb Pharma Company | Synthesis of 1,3,5-trisubstituted pyrazoles |
EP1226123A1 (en) * | 1999-11-03 | 2002-07-31 | Du Pont Pharmaceuticals Company | Cyano compounds as factor xa inhibitors |
US6407256B1 (en) | 1999-11-03 | 2002-06-18 | Bristol Myers Squibb Co | Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors |
AU2001268712A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Company | 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor Xa inhibitors |
TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
JP4249621B2 (en) | 2001-09-21 | 2009-04-02 | ブリストル−マイヤーズ スクイブ カンパニー | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
PE20030547A1 (en) | 2001-09-24 | 2003-08-18 | Bayer Corp | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF OBESITY |
AU2002350217A1 (en) | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
TW200302225A (en) | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
WO2003099276A1 (en) | 2002-05-10 | 2003-12-04 | Bristol-Myers Squibb Company | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
ES2543588T3 (en) | 2002-12-03 | 2015-08-20 | Pharmacyclics Llc | 2- (2-Hydroxybiphenyl-3-yl) -1H-benzoimidazol-5-carboxamidine derivatives as inhibitors of factor VIIa |
EP1479678A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Pyrazole-derivatives as factor xa inhibitors |
EP1433788A1 (en) * | 2002-12-23 | 2004-06-30 | Aventis Pharma Deutschland GmbH | Pyrazole-derivatives as factor Xa inhibitors |
US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
BR0317659A (en) * | 2002-12-23 | 2005-12-06 | Aventis Pharma Gmbh | Pyrazole derivatives as factor xa inhibitors |
US7122557B2 (en) * | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
US20040220170A1 (en) * | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
EP1620405A2 (en) * | 2003-05-01 | 2006-02-01 | Abbott Laboratories | Pyrazole-amides and sulfonamides as sodium channel modulators |
EP1479679A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Triazole-derivatives as factor Xa inhibitors |
US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
NZ544756A (en) | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
WO2005009954A2 (en) * | 2003-07-23 | 2005-02-03 | Synta Pharmaceuticals, Corp. | Method for modulating calcium ion-release-activated calcium ion channels |
WO2005037271A2 (en) * | 2003-10-17 | 2005-04-28 | Tanabe Seiyaku Co., Ltd. | Large conductance calcium-activated k channel opener |
EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
TWI357901B (en) * | 2004-03-12 | 2012-02-11 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivati |
MX2007008290A (en) | 2005-01-07 | 2008-02-15 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses. |
AR054425A1 (en) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO. |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
EP1867331A4 (en) | 2005-04-06 | 2009-04-08 | Takeda Pharmaceutical | Triazole derivative and the use thereof |
WO2008051405A1 (en) | 2006-10-20 | 2008-05-02 | Merck & Co., Inc. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
MX2009004112A (en) | 2006-10-20 | 2009-05-11 | Merck & Co Inc | Substituted imidazoles as bombesin receptor subtype-3 modulators. |
AU2007309568A1 (en) | 2006-10-20 | 2008-05-02 | Merck Sharp & Dohme Corp. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
JP2010509392A (en) | 2006-11-13 | 2010-03-25 | ファイザー・プロダクツ・インク | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
US8153626B2 (en) | 2006-12-11 | 2012-04-10 | Merck Sharp & Dohme Corp. | Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators |
CA2679198C (en) | 2007-02-26 | 2011-07-12 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
KR20150033678A (en) | 2012-06-26 | 2015-04-01 | 사니오나 에이피에스 | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
JP6223443B2 (en) | 2012-06-26 | 2017-11-01 | サニオナ・エイピイエス | Use of phenyltriazole derivatives and GABAA receptor complex for modulating GABAA receptor complex |
CN113243374B (en) | 2012-10-02 | 2022-04-26 | 拜耳农作物科学股份公司 | Heterocyclic compounds as pesticides |
CN105189456B (en) * | 2013-03-15 | 2017-12-19 | 亚瑞克西斯制药公司 | KRAS G12C covalency inhibitor |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
JO3805B1 (en) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | Inhibitors of kras g12c |
SG10202001795XA (en) | 2014-03-07 | 2020-04-29 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
CN104072436B (en) * | 2014-07-23 | 2015-10-14 | 张远强 | The tetrazole acetophenone compound of para-orientation, Preparation Method And The Use |
CN104086502B (en) * | 2014-07-23 | 2015-10-14 | 张远强 | Halo tetrazole acetophenone compound, Preparation Method And The Use |
CN104072439B (en) * | 2014-07-23 | 2015-11-04 | 张远强 | The tetrazole acetophenone compound of halogen substiuted, Preparation Method And The Use |
CN104072438B (en) * | 2014-07-23 | 2015-10-14 | 张远强 | Dialkoxy is for tetrazole acetophenone compound, Preparation Method And The Use |
US10246424B2 (en) | 2015-04-10 | 2019-04-02 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
CA3005089A1 (en) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
CN110312711A (en) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | Heterocyclic compound and its application method as RAS inhibitor |
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
US11059819B2 (en) | 2017-01-26 | 2021-07-13 | Janssen Biotech, Inc. | Fused hetero-hetero bicyclic compounds and methods of use thereof |
WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
MX2019013954A (en) | 2017-05-25 | 2020-08-31 | Araxes Pharma Llc | Covalent inhibitors of kras. |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
KR20000062284A (en) * | 1996-12-23 | 2000-10-25 | 블레어 큐. 퍼거슨 | Nitrogen containing heteroaromatics as factor Xa inhibitors |
ES2239806T3 (en) * | 1997-06-19 | 2005-10-01 | Bristol-Myers Squibb Pharma Company | XA FACTOR INHIBITORS WITH A P1 NEUTRAL SPECIFICITY GROUP. |
-
1998
- 1998-12-11 JP JP2000525391A patent/JP2001526268A/en not_active Withdrawn
- 1998-12-11 IL IL13663798A patent/IL136637A0/en unknown
- 1998-12-11 AU AU17244/99A patent/AU1724499A/en not_active Abandoned
- 1998-12-11 BR BR9813835-9A patent/BR9813835A/en not_active Application Discontinuation
- 1998-12-11 CA CA002314401A patent/CA2314401A1/en not_active Abandoned
- 1998-12-11 WO PCT/US1998/026427 patent/WO1999032454A1/en not_active Application Discontinuation
- 1998-12-11 EP EP98962082A patent/EP1042299A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2001526268A (en) | 2001-12-18 |
IL136637A0 (en) | 2001-06-14 |
CA2314401A1 (en) | 1999-07-01 |
AU1724499A (en) | 1999-07-12 |
WO1999032454A9 (en) | 2001-05-31 |
WO1999032454A1 (en) | 1999-07-01 |
EP1042299A1 (en) | 2000-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9813835A (en) | Compound, pharmaceutical composition and method of treatment or prevention of a thromboembolic disorder | |
BR9917080A (en) | Compound, pharmaceutical composition, use of the compound and method of treatment or prevention of thromboembolic dysfunction | |
BR9810137A (en) | Compound, pharmaceutical composition and method of treatment or prevention of a thromboembolic disorder | |
BR9810151A (en) | Compound, pharmaceutical composition and method for treating or preventing a thromboembolic disorder | |
BR0201437A (en) | Process for preparing 4-substituted 9-deoxo-9a-aza-9a-homoerythromycin derivatives | |
BR9913138A (en) | Quinolin-2-one derivatives substituted with alkynyl useful as agents against cancer | |
BR0108610A (en) | Azapolycyclic compounds condensed with aryl | |
BR9802851A (en) | Macrolide antibiotics replaced by c-4 | |
EA199900591A1 (en) | NITROGEN-CONTAINING HETEROAROMATIC COMPOUNDS AS INHIBITOR FACTOR XA | |
TR200001279T2 (en) | Poly (ADP-ribose) polymerase ("PARP") inhibitors, methods and pharmaceutical compositions for the treatment of neural and cardiovascular tissue damage. | |
BR0116115A (en) | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumors. | |
BRPI0415437A (en) | compound, process for the preparation and use thereof, pharmaceutical composition, process for the preparation thereof, and, product | |
BR9507995A (en) | Compound use of the compound intermediate pharmaceutical formulation and processes for the preparation of a compound and intermediate and for treating a condition in which there is an advantage in inhibiting the production of no from l-arginine by the action of no synthase | |
BRPI0507818A (en) | compound and inhibition methods | |
BR0205890A (en) | Pyrazolopyrimidines as therapeutic agents | |
BR0012590A (en) | Compound, process for its preparation, pharmaceutical formulation, use of a compound, and, methods for treatment or prophylaxis of pain or discomfort, and for treatment or prophylaxis of neuropathic or central pain | |
DK1265606T3 (en) | cell adhesion inhibitors | |
BR0211305A (en) | Compound, pharmaceutical composition, method of treating or preventing disease or conditions and use of a compound | |
BR0210531A (en) | Sulfonic Acid Derivatives | |
BRPI0409211A (en) | compound, pharmaceutical composition, methods for activating 5-ht1f receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal, and, use of a compound | |
BR9914998A (en) | Macrolid antibiotics | |
BR9908470A (en) | Compound, pharmaceutical composition, and process to treat conditions mediated by avb3 inegrin in a mammal in need of such treatment | |
BR0113389A (en) | Compounds that inhibit factor xa activity | |
BRPI0417345A (en) | azole-based kinase inhibiting compounds, compositions and their uses | |
BR0309188A (en) | Pyrazole compounds as antiinflammatory and analgesic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |